Regarding the pathogenesis and molecular biology of osteosarcoma, all of the following are true EXCEPT:

Explanation

## Osteosarcoma Pathogenesis: Molecular & Genetic Basis ### Genetic Predisposition **Key Point:** Germline **TP53 mutations** (Li-Fraumeni syndrome) and **RB1 inactivation** (hereditary retinoblastoma) are the two most strongly associated genetic risk factors for osteosarcoma. Patients with these syndromes have dramatically increased lifetime risk. **High-Yield:** ~10% of osteosarcoma patients have a family history of cancer or carry germline TP53 mutations, making genetic screening important in young patients with osteosarcoma. ### Cell of Origin & Growth Context **Clinical Pearl:** Osteosarcoma arises from **malignant transformation of osteoblasts** during periods of rapid skeletal growth—hence the peak incidence in adolescents and during growth spurts. The tumor emerges *de novo* from normal bone, not from pre-existing benign lesions. ### Molecular Alterations | Alteration | Frequency | Significance | |-----------|-----------|-------------| | **TP53 loss** | 50–70% | Loss of cell cycle checkpoint control | | **RB1 inactivation** | 50–60% | Loss of G1/S checkpoint | | **MYC amplification** | 10–30% | Oncogenic drive and proliferation | | **Growth factor overexpression** | Common | PDGF, FGF, IGF-1 signaling activation | | **p16/CDKN2A deletion** | Frequent | Loss of CDK inhibitor | ### Why Option 3 (Pre-existing Benign Lesions) Is Wrong **Warning:** This is a common misconception. Unlike some other bone tumors (e.g., giant cell tumor, chondrosarcoma from osteochondroma), osteosarcoma does **NOT** arise from malignant transformation of benign precursor lesions. It arises *de novo* from normal bone during rapid growth. This distinction is critical for exam success. ### Contrast with Other Bone Tumors | Tumor | Arises from Benign Precursor? | |-------|------------------------------| | **Osteosarcoma** | No — de novo from normal bone | | **Chondrosarcoma** | Often — from osteochondroma or enchondroma | | **Malignant fibrous histiocytoma** | Rarely — may arise from fibrous dysplasia | | **Giant cell tumor** | No — primary malignant lesion | ### Pathogenesis Summary 1. Germline or somatic TP53/RB1 mutations predispose cells to malignant transformation 2. Rapid osteoblast proliferation during growth provides a permissive environment 3. Additional oncogenic hits (MYC, growth factor signaling) drive full malignant transformation 4. Result: de novo high-grade malignancy with early metastatic potential